• SHEEBA F. R. Mallige College of Pharmacy, Bangalore 90
  • KUNDAN CHAUDHARY Mallige College of Pharmacy, Bangalore 90


Objective: In the present study, the effects of a natural superdisintegrant gellan gum, karya synthetic gum superdisintegrants like sodium starch glycolate, crospovidone and combination of natural and synthetic superdisintegrant were compared in the formulations of rizatriptan benzoate oral dispersible tablets.

Methods: This oral dispersible tablets were prepared by direct compression method and evaluated for weight variation, hardness, disintegration time, drug content, friability and dissolution. Drug compatibility with excipients was checked by FTIR studies. Stability study of the prepared tablets was done at 40±2°/75%±5% RH for a period of 1 mo.

Results: FTIR studies showed that no any chemical interaction between drugs and excipients. The in vitro drug release study revealed that formulation F9 combination of both crospovidone and karya gum was the most successful formulation and disintegrate time within 13 seconds and drug release within 10 min. The drug release from the best formulations followed first-order kinetics, which is concentration-dependent. Short terms stability studies of the tablet for three months showed non-significant drug loss.

Conclusion: The formulation containing a combination of natural and synthetic superdisintegrant was found to be the best results. Apart from fulfilling all official and other specifications, the tablets exhibited a higher rate of drug release.

Keywords: Orally dispersible tablets, Natural and synthetic superdisintegrants, Rizatriptan benzoate


1. Rewar S, Singh CJ, Bansal BK, Pareek R, Sharma AK. Oral dispersible tablet: an overview; development, technologies and evaluation. Int J Res Dev Pharma Life Sci 2014;3(4, Suppl 6):1223-35.
2. Malay KB Chotaliya, Sumit Chakraborty. Overview of the oral dispersible tablet. Int J Pharma Tech Res 2012;4 Suppl 4:1712-20.
3. Kushagra K, Gauravi Xavier, Suresh KJ, Aashish P, Sakshum K, Vipin, et al. Fast dissolving tablet-a novel approach. Int J Pharm Res Allied Sci 2016;5 Suppl 2:311-22.
4. Mothilal M, Srikanth K, Sivagirish Babu G, Gnanedra K, Manimaran V, Damodharan N. Formulation and evaluation of rizatriptan benzoate orally disintegrating tablets. Int J Drug Dev Res 2012:4 Suppl 2:117-23.
5. Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets of salbutamol sulphate: a novel drug delivery system. Indian Drugs 2004;41:592–8.
6. Indian Pharmacopoeia. 4th ed. Vol. 2. New Delhi: The Controller of Publications; 1996. p. 735–6.
7. Sheetal B, Raval K, Sandip B. Formulation and evaluation of fast dissolving tablets of amlodipine and rosuvastatin. Int J Pharm Bio Sci 2015:2 Suppl 1:1-12.
8. Laxmi CSR, Nitesh JP, Hitesh P, Sagar P. Formulation and evaluation of oral dispersible tablets of cinnarizine using sublimation technique. Int J Pharma sci Rev Res 2011:6 Suppl 2:178-82.
9. Kangala Vijaya S, Geed Bharat R, Dashmukhi R, Chitimalla Ajay K. Preparation and evaluation of montelukast oral dispersible tablets by direct compression. Int Res J Pharm 2012:3 Suppl 7:315-8.
10. Sunil Kumar BG, Felix JV, Vishwanath BA. Formulation and evaluation of dispersible tablet of cefixime trihydrate. Int J Pharma Drug Analysis 2014:2 Suppl 1:858-68.
11. Suddheshnababu S, Sai Kishore V. Formulation and evaluation of fast dissolving tablets of Amlodipine besylate by using fenugreek seed mucilage and ocimum gum. Int Curr Pharma J 2012:1 Suppl 9:243-9.
12. Bi Y, Sunada H, Yonezawa Y, Danjo K, Iida K. Preparation and evaluation of compressed tablets rapidly disintegration in the oral cavity. Chem Pharm Bull 1996;44:2121–7.
13. Klanche J. Dissolution testing of orally disintegrating tablets. CIMA LABS INC Dissolution Technol 2003. p. 6-8.
14. Shenoy V, Pandey S, Agarwal S. Optimizing fast-dissolving dosage form of diclofenac sodium by rapidly disintegrating agents. Indian J Pharm Sci 2003;4:197-201.
28 Views | 20 Downloads
How to Cite
F. R., S., and K. CHAUDHARY. “COMPARATIVE STUDY ON EFFECT OF NATURAL AND SYNTHETIC SUPERDISINTEGRANTS IN THE FORMULATION OF RIZATRIPTAN BENZOATE ORAL DISPERSIBLE TABLETS”. International Journal of Current Pharmaceutical Research, Vol. 12, no. 4, July 2020, pp. 114-7, doi:10.22159/ijcpr.2020v12i4.39096.
Original Article(s)